Reactive arthritis · Clinical perspective · Chapter 01
Reactive Arthritis Within the SpA Spectrum
An infection-linked syndrome needs a coherent phenotype, a plausible timeline and a diagnosis that remains open to revision.
On this page
Define the syndrome before naming the trigger
Classic reactive arthritis (ReA) is an inflammatory musculoskeletal syndrome arising after a gastrointestinal or genitourinary infection, usually with a delay of days to several weeks. Asymmetric lower-limb arthritis, enthesitis and dactylitis place it within the spondyloarthritis (SpA) spectrum. Uveitis, mucocutaneous lesions and axial symptoms can reinforce that pattern. None is individually diagnostic. [1]
The useful distinction is between a joint infected by a microorganism and inflammation associated with an infection elsewhere. In ReA, routine synovial culture does not identify a causative organism in the way it may in septic arthritis. Calling the joint “sterile,” however, oversimplifies the biology: microbial components and, in selected chlamydial disease, evidence of microbial persistence have been demonstrated. Neither formulation licenses skipping aspiration when infection is plausible.
Keep the case definition narrow enough to be useful
Chlamydia trachomatis and the enteric pathogens Salmonella, Shigella, Campylobacter and Yersinia are the conventional starting point. An unverified viral illness, an isolated positive antibody result or a commercial stool panel does not provide equivalent evidence. Broader infection-associated arthritides exist, but grouping all of them under classic ReA conceals differences in prognosis and treatment.
Record three things separately: the inflammatory phenotype, the evidence for the antecedent infection, and the strength of the causal connection. “Probable postenteric reactive arthritis after a documented Campylobacter illness” communicates more than “HLA-B27 arthritis.” When the trigger is uncertain, that uncertainty belongs in the assessment rather than being repaired by indiscriminate testing.
Why this belongs in SpA
The shared territory is clinical and biological: entheses, peripheral joints, sometimes the sacroiliac joints, overlapping extra-articular disease and an association with HLA-B27. This does not mean that every patient has axial SpA or will develop radiographic sacroiliitis. Conversely, an infection may draw attention to a previously evolving SpA phenotype rather than explain the entire illness.
HLA-B27 changes probability in context. It cannot prove the cause of an episode or predict one person's course. Background prevalence, referral selection and the definition of persistent disease all affect associations reported by cohorts. A negative result does not exclude ReA; a positive result in a person with mechanical pain does not create it. [2]
Explain persistence without promising an eradication cure
Immune activation after infection can outlast the symptoms that first brought the patient to medical attention. Proposed mechanisms include retained microbial material, altered host responses and, in selected chlamydial disease, persistent organisms. These are explanatory models with uneven clinical testability, not a menu of biomarkers that can identify the mechanism in every patient.
This distinction matters therapeutically. Treat an active infection for its own indication. Treat synovitis and functional loss according to their severity. The limited trial evidence for prolonged combination antibiotics in a highly selected chronic chlamydial population cannot be generalized to an unexplained persistent knee effusion. [3]
Classification is not a substitute for diagnosis
Research definitions help assemble comparable groups; they are not a universally validated diagnostic rule for an individual patient. The historical arthritis–urethritis–conjunctivitis triad is particularly unhelpful as an entry requirement. Many patients never have all three features, and genital infection may have been asymptomatic.
Likewise, satisfying peripheral SpA classification criteria does not distinguish ReA from psoriatic arthritis or IBD-associated arthritis. Use those features to organize the phenotype, then test the competing explanations. The question is not simply whether the patient fits a category, but whether the category explains the whole illness better than the alternatives.
A working diagnosis should contain a follow-up plan
A practical assessment states the onset and distribution of inflammation; the suspected or confirmed trigger and dates; the urgent alternatives evaluated; any eye, bowel, skin or axial involvement; and what remains uncertain. Set a review date and define what would prompt earlier reassessment.
Persistent disease should trigger renewed examination for psoriasis, inflammatory bowel disease and an evolving axial phenotype. Reclassification is not failure. It may be the most accurate response to new information. The module therefore returns to diagnostic reassessment after the treatment chapters rather than treating the first label as permanent.
Sources and further reading
- NIAMS. Reactive Arthritis: overview, diagnosis, treatment and steps to take.
- American College of Rheumatology. Reactive Arthritis. Patient information, updated 2025.
- Carter JD et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62:1298–1307.
- Carlin E, Marzo-Ortega H, Flew S. British Association for Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021.
Educational information. Your treatment plan depends on your examination, test results and medical history.